Skip to Content

A Specialist Service

M2 (or Monash MedTech) is a joint venture between CSIRO, Monash University and the Monash Health Translation Precinct (MHTP). Located in the City of Monash, it helps companies meet the translational challenges of the medical technologies (MedTech) industry by providing a broad range of equipment and technical expertise.

Email the M2 Business Manager


M2 specialises in the development of biomedical materials and coatings, regenerative medicine and advanced biomedical imaging. Medical technology (also known as MedTech) is one of the fastest growing high tech sectors, with more than 500 companies in Australia alone. Many of these are Small and Medium Enterprises (SMEs), which sometimes struggle to transition from R&D and initial offering, to a sustainable product.

By combining its members’ extensive expertise, experience and resources M2 bridges this critical capability gap in the Australian MedTech SME value chain. It provides the research infrastructure to rapidly transition new discoveries from the bench to scale-up, prototyping, pre-clinical testing, industry evaluation and adoption.


  • Monash Biomedical Imaging

    Non-invasive human imaging with a suite of consulting rooms. Small and large animal pre-clinical imaging and research infrastructure.

    • MR-PET scanner capable of simultaneous MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans (60cm bore - large enough for humans and large animals)
    • Small animal PET and computed tomography for device imaging
    • Radiopharmacy and radiochemistry laboratories - for preparation and dispensing of radiopharmaceuticals


    Materials synthesis & processing, surface modification, biological testing and evaluation.

    • High throughput biological testing and materials evaluation in a PC2 laboratory
    • ISO Class 7 cleanroom for materials synthesis, processing, fabrication, and surface coating
    • High temperature furnace for preparation of ceramic biomaterials

  • Monash Health Translation Precinct

    Cell Therapies and Regenerative Medicine Platform.

    • 3D Bioprinting capabilities within GMP environment
    • BioSpherix Xvivo isolator system for GMP cell and tissue manufacturing
    • Clinical cell sorting capabilities in an ISO Class 8 cleanroom suite


  • Leading Edge Research

    • High throughput synthesis
    • Latest fabrication technologies, including 3D printing
    • Suite of coating technologies
    • High throughput biological testing
    • Real-time non-invasive imaging
    • Multimodal in-vivo and ex-vivo device imaging
    • Suite of animal models for pre-clinical research

  • Ready for Industry

    • ISO Class 7 Cleanroom
    • Quality management systems including Good Laboratory & Manufacturing Practice (GLP/GMP)
    • Service via experienced operators
    • Industrially-relevant production equipment within a research environment
    • Industrially-accessible, cost-effective preclinical research; IS09001: 2008
    • Industry and research collaborators can access facility via service provision or research collaboration
    • Industry staff embedded in facility


  • Joint R&D programs

    Collaborative research programs that make use of M2 expertise and infrastructure for mutual benefit of the research and industry partners.

  • Direct access

    M2 provides relevant training in order that outside staff can make use of M2 equipment to develop their own products.

  • Service provision

    M2 provides a turn-key solution to your research needs, taking your idea, concept or prototype and turning it into a reality, without needing to be an expert in biomedical materials.


  • Gary Egan

    Director, MBI
    t: +61 3 9905 0100

  • Mark Bown

    Principal Research Scientist, CSIRO
    t: +61 3 9545 8049

  • Gordon McPhee

    Operations Manager,
    MHTP Cell Therapies
    & Regenerative Medicine Platform

    t: 0498 053 294

  • Richard Huysmans

    M2 Business Manager
    t: 0412 606 178